Catalyst Pharmaceuticals, Inc. $CPRX Position Raised by Vanguard Group Inc.

Key Points

• Vanguard Group Inc. increased its stake in Catalyst Pharmaceuticals by 0.8%, acquiring an additional 64,486 shares, bringing their total ownership to approximately 8.5 million shares, valued at $206 million.
• Other institutional investors are also actively increasing their stakes, including Bank of America, which boosted its position by 139.5%.
• Wall Street analysts have mixed reviews for Catalyst Pharmaceuticals, with one downgrading the stock from a "strong-buy" to a "hold", while others maintain a generally positive outlook with an average price target of $33.20.

Vanguard Group Inc. grew its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 0.8% in the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 8,495,580 shares of the biopharmaceutical company's stock after buying an additional 64,486 shares during the quarter. Vanguard Group Inc. owned 6.97% of Catalyst Pharmaceuticals worth $206,018,000 as of its most recent filing with the SEC.

Other large investors also recently bought and sold shares of the company. Park Square Financial Group LLC purchased a new stake in shares of Catalyst Pharmaceuticals during the 4th quarter worth $29,000. Sound Income Strategies LLC purchased a new position in shares of Catalyst Pharmaceuticals in the first quarter valued at $64,000. GAMMA Investing LLC increased its position in shares of Catalyst Pharmaceuticals by 26.2% in the first quarter. GAMMA Investing LLC now owns 2,791 shares of the biopharmaceutical company's stock valued at $68,000 after buying an additional 579 shares in the last quarter. Quarry LP purchased a new position in shares of Catalyst Pharmaceuticals in the fourth quarter valued at $104,000. Finally, PNC Financial Services Group Inc. increased its position in shares of Catalyst Pharmaceuticals by 57.2% in the first quarter. PNC Financial Services Group Inc. now owns 5,501 shares of the biopharmaceutical company's stock valued at $133,000 after buying an additional 2,002 shares in the last quarter. Hedge funds and other institutional investors own 79.22% of the company's stock.

Insider Transactions at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, insider Preethi Sundaram sold 1,600 shares of the stock in a transaction on Wednesday, June 11th. The shares were sold at an average price of $26.42, for a total transaction of $42,272.00. Following the transaction, the insider directly owned 41,081 shares in the company, valued at $1,085,360.02. This represents a 3.75% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 10.40% of the stock is owned by company insiders.

Catalyst Pharmaceuticals Stock Performance

Catalyst Pharmaceuticals stock traded up $0.52 during trading on Friday, reaching $21.08. 1,110,487 shares of the company's stock were exchanged, compared to its average volume of 1,440,265. Catalyst Pharmaceuticals, Inc. has a 52-week low of $19.00 and a 52-week high of $26.58. The firm has a market cap of $2.58 billion, a price-to-earnings ratio of 12.78, a PEG ratio of 0.86 and a beta of 0.70. The company's 50-day moving average is $21.29 and its two-hundred day moving average is $22.60.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on CPRX shares. Zacks Research downgraded shares of Catalyst Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Tuesday, August 19th. Wall Street Zen downgraded Catalyst Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Saturday, August 9th. Finally, Cantor Fitzgerald raised Catalyst Pharmaceuticals to a "strong-buy" rating in a research report on Thursday, June 5th. Two analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $33.20.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.